All In MedTech

FDA Clearance Tracker · P050037-S110

RADIESSE Injectable Implant

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Aug 27, 2021 (this decision)Source: openFDAMethods & limitations

PMA supplement

The decision

FDA number
P050037-S110
Device name
RADIESSE Injectable Implant
Applicant location
Franksville, WI
Received
Nov 20, 2020
Decided
Aug 27, 2021
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P050037

Device type

Device class
Class III

Every decision under product code LMH

FDA's approval statement

As written in FDA's record.

Approval for modification of the Calcium Hydroxylapatite (CaHA) particle manufacturing process to allow for an Alternate Processing Pathway (APP) to process CaHA particle byproducts.

Source documents

Other decisions for Merz North America, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

6 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.